Clinical Trial Update: Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 Japan expansion cohort update comparing Belantamab Mafodotin with Bortezomib and Dexamethasone versus Daratumumab with Bortezomib and Dexamethasone in r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• Velcade (bortezomib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-09